Parekh Has First Mover s Advantage in Taking Proteomics to Drugs

Mar 25, 2002

Premium

AT A GLANCE

Name: Raj B. Parekh

Position: Chief Scientific Officer, Oxford GlycoSciences

Prior Experience: Founding Research Director of OGS, a
spin-off of the Oxford University Department of Biochemistry

How did OGS first become involved in proteomics?

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

And Deal

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Positive Review

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

For Long Life

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

This Week in Nucleic Acids Research

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.

Featured White Papers

Stroma Liquid Biopsy - Biomarkers of the Dysregulation of the Serum Proteome in Cancer

Cleanascite Lipid Removal & Clarification Reference Applications

Albumin Removal Reference Applications

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Main menu